Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase.
Luo
Y
Y
Lai
X-Y
XY
Tan
Y-M
YM
Shi
J-M
JM
Zhao
Y-M
YM
Han
X-Y
XY
Zheng
G-F
GF
Zhu
X-L
XL
Sun
J
J
Zheng
Y-L
YL
Wu
G-Q
GQ
He
J-S
JS
Chen
S-Y
SY
Jin
A-Y
AY
Xie
W-Z
WZ
Ye
X-J
XJ
Cai
Z
Z
Lin
M-F
MF
Huang
H
H
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate